The treatment for sinusitis in an adult WITH risk factors for pneumococcal resistance and no drug allergies is:

Rationale: A. Sulfamethoxazole/Trimethoprim is not recommended for the treatment of acute bacterial rhinosinusitis when resistance is suspected because Streptococcus pneumoniae has high rates of resistance to this agent. Using a sulfonamide in a patient with risk factors for resistance would likely lead to clinical failure and the persistence of the sinus infection. It does not provide the robust coverage necessary for high-risk bacterial strains. B. Cephalexin is a first-generation cephalosporin that lacks adequate coverage for the common pathogens associated with sinusitis, such as Haemophilus influenzae and resistant Streptococcus pneumoniae. It is primarily effective against Gram-positive skin flora and is not considered an appropriate choice for respiratory tract infections. Relying on this agent would fail to address the likely bacterial culprits in an adult with resistance risk factors. C. While levofloxacin is effective against resistant pneumococcus, it is generally reserved as a second-line or alternative agent due to its broad-spectrum nature and potential for severe side effects. Current antimicrobial stewardship guidelines prioritize beta-lactam/beta-lactamase inhibitor combinations over fluoroquinolones for initial therapy to preserve the efficacy of the latter. Fluoroquinolones should only be used when first-line options are inappropriate or have failed. D. High-dose Amoxicillin/clavulanate is the preferred first-line treatment for adults with risk factors for resistant Streptococcus pneumoniae. The addition of clavulanate overcomes resistance provided by beta-lactamase-producing organisms like Moraxella catarrhalis. This combination ensures that the antibiotic remains effective against the most common and difficult-to-treat pathogens found in the paranasal sinuses while maintaining a relatively safe profile.